Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic of
respiratory and cardiovascular diseases, known as coronavirus disease 2019 (COVID-19) …

Background There are limited antiviral options for the treatment of patients with COVID-19.
Ivermectin (IVM), a macrocyclic lactone with a wide anti-parasitary spectrum, has shown …

Nucleoside analogs are a major class of antiviral drugs. Some act by increasing the viral
mutation rate causing lethal mutagenesis of the virus. Their mutagenic capacity, however …

Mathematical models of viral dynamics have been reported to describe adequately the
dynamic changes of severe acute respiratory syndrome‐coronavirus 2 viral load within an …

Severe acute respiratory syndrome coronavirus 2 or SARS-CoV-2 is a virus that belongs to
the Coronaviridae family. This group of viruses commonly causes colds but possesses a …

Over the past two years, several variants of SARS-CoV-2 have emerged and spread all over
the world. However, infectivity, clinical severity, re-infection, virulence, transmissibility …

Background The nitazoxanide plus atazanavir/ritonavir for COVID-19 (NACOVID) trial
investigated the efficacy and safety of repurposed nitazoxanide combined with …

More than two years have passed since the viral outbreak that led to the novel infectious
respiratory disease COVID-19, caused by the SARS-CoV-2 coronavirus. Since then, the …

Nuclear transport and vesicle trafficking are key cellular functions involved in the
pathogenesis of RNA viruses. Among other pleiotropic effects on virus-infected host cells …

The COVID-19 pandemic has posed a challenge to public health systems worldwide. As of
March 2022, almost 500 million cases have been reported worldwide. More than 6.2 million …